Abstract

The Hippo signaling pathway regulates cellular proliferation and survival, thus exerting profound effects on normal cell fate and tumorigenesis. Pivotal effectors of this pathway are YAP/TAZ, transcriptional co-activators whose dysfunction contributes to epithelial-to-mesenchymal transition and malignant transformation. Therefore, it is of great importance to decipher the mechanisms underlying the regulations of YAP/TAZ at various levels. Here we report that non-receptor tyrosine phosphatase 14 (PTPN14) interacts with the Kibra protein. The interaction between PTPN14 and Kibra is through the PPXY domain of PTPN14 and WW domain of Kibra. PTPN14 and Kibra can induce the LATS1 activation independently and cooperatively. Interestingly, activation of LATS1 by PTPN14 is dependent on the C terminus of PTPN14 and independent of the upstream mammalian STE20-like kinase (MST) proteins. Furthermore, we demonstrate that PTPN14 increases the LAST1 protein stability. Last, overexpression of Kibra rescues the increased cell migration and aberrant three-dimensional morphogenesis induced by knockdown of PTPN14, and this rescue is mediated through the activation of the upstream LATS1 kinase and subsequent cytoplasmic sequestration of YAP. In summary, our results indicate a potential regulatory role of PTPN14 in the Hippo pathway and demonstrate another layer of regulation in the YAP oncogenic function.

Highlights

  • Transcriptional co-activators YAP/TAZ are pivotal effectors of the Hippo pathway and their dysfunction promote epithelial-to-mesenchymal transition (EMT) and malignant transformation

  • Interaction with PTPN14 was completely lost when both WW domains were deleted (Fig. 1C). These results indicated that PTPN14 interacts with Kibra through its C-terminal and PPXY domains, whereas Kibra interacts with PTPN14 through at least one WW domain

  • We have proven that PTPN14 interacts with Kibra and LATS1 both exogenously and endogenously

Read more

Summary

Background

Transcriptional co-activators YAP/TAZ are pivotal effectors of the Hippo pathway and their dysfunction promote epithelial-to-mesenchymal transition (EMT) and malignant transformation. Results: PTPN14 interacts with Kibra and activates LATS1 (upstream negative regulator of YAP). Conclusion: PTPN14 and Kibra activate LATS1 and negatively regulate the YAP oncogenic function. The Hippo signaling pathway regulates cellular proliferation and survival, exerting profound effects on normal cell fate and tumorigenesis Pivotal effectors of this pathway are YAP/ TAZ, transcriptional co-activators whose dysfunction contributes to epithelial-to-mesenchymal transition and malignant transformation. Overexpression of Kibra rescues the increased cell migration and aberrant three-dimensional morphogenesis induced by knockdown of PTPN14, and this rescue is mediated through the activation of the upstream LATS1 kinase and subsequent cytoplasmic sequestration of YAP. In light of the recent findings, we decided to examine whether mammalian PTPN14 interacts with Kibra and whether they play any cooperative role together in regulating the YAP/TAZ oncogenic functions. All results are expressed as mean Ϯ S.D. *, p Ͻ 0.05; **, p Ͻ 0.001; ***, p Ͻ 0.0001

RESULTS
C2 C2 C2
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call